Published on
Apr 23, 2026
<![CDATA[New Frontiers in Adjuvant Care: Evaluating Elacestrant in the ELEGANT Trial]]>
For patients with high-risk, estrogen receptor—positive, HER2-negative early breast cancer, the standard of care has long relied on adjuvant endocrine therapy (ET) to mitigate the risk of late recurrence. However, despite these interventions, a significant …
Source:
Cancer Network
-
Pending
